EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Pulmonology

Eddie Needham, MD
Program Director and Academic Chairman
AdventHealth Winter Park
Family Medicine Residency Program
Professor, Loma Linda University School of Medicine
Eddie.Needham.MD@AdventHealth

# Lecture Modules

- Asthma
- PFT interpretation
- Miscellaneous
  - Sarcoidosis
  - Venous thromboembolism, DVT/PE
- Pneumonia
- CXRs
- COPD

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Abbreviations

- LABA = long-acting beta agonist
- SABA = short-acting beta agonist
- LAMA = long-acting muscarinic antagonist
- SAMA = short-acting muscarinic antagonist
- ICS = inhaled corticosteroid
- LTRA = leukotriene receptor antagonist

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Which of the following medication choices for steps 1-2 asthma is a **preferred** GINA treatment option?

A. Salmeterol 50 mcg,  1 puff bid maintenance and albuterol rescue
B. Budesonide/formoterol (80/4.5 mcg) bid maintenance and rescue
C. Fluticasone 110 mcg, 2 puffs bid + montelukast 10 mg qHS maintenance and albuterol rescue
D. Fluticasone + salmeterol (250/50) mcg 1 puff PRN

# Correct Answer is B

- Answer A – LABA/SABA is not an approved asthma treatment
- Answer C – ICS/LTRA with SABA is an option but not preferred
- Answer D – ICS/LABA with salmeterol is not a preferred option

# A reminder – the key change in GINA 2019

EDITORIAL
GINA 2019

## GINA 2019: a fundamental change in asthma management

Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents

Helen K. Reddel[1], J. Mark FitzGerald[2], Eric D. Bateman[3], Leonard B. Bacharier[4], Allan Becker[5], Guy Brusselle[6], Roland Buhl[7], Alvaro A. Cruz[8], Louise Fleming[9], Hiromasa Inoue[10], Fanny Wai-san Ko[11], Jerry A. Krishnan[12], Mark L. Levy[13], Jiangtao Lin[14], Søren E. Pedersen[15], Aziz Sheikh[16], Arzu Yorgancioglu[17] and Louis-Philippe Boulet[18]

@ERSpublications
**GINA no longer recommends treating adults/adolescents with asthma with short-acting bronchodilators alone. Instead, they should receive symptom-driven (in mild asthma) or a daily corticosteroid-containing inhaler, to reduce risk of severe exacerbations.** http://bit.ly/310LLzE

**Cite this article as:** Reddel HK, FitzGerald JM, Bateman ED, *et al.* GINA 2019: a fundamental change in asthma management. *Eur Respir J* 2019; 53: 1901046 [https://doi.org/10.1183/13993003.01046-2019].

# GINA 2019 – landmark changes in asthma management

- For safety, GINA no longer recommends SABA-only treatment for Step 1 in adults and adolescents
  - This decision was based on evidence that SABA-only treatment increases the risk of severe exacerbations, and that adding any ICS significantly reduces the risk
- GINA now recommends that all adults and adolescents with asthma should receive ICS-containing controller treatment, to reduce the risk of serious exacerbations
  - The ICS can be delivered by regular daily treatment or, in mild asthma, by as-needed low dose ICS-formoterol
- This is a population-level risk reduction strategy
  - Other examples: statins, anti-hypertensives
  - The aim is to reduce the probability of serious adverse outcomes at a population level
  - Individual patients may not necessarily experience (or be aware of) short-term clinical benefit

ICS: inhaled corticosteroids; SABA: short-acting beta$_2$-agonist

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Global Initiative in Asthma (GINA) 2021

- International guideline for asthma
- Advocate for regular or prn ICS/LABA in step 1 patients
- Asthma classifications: mild, moderate, severe
  - They do not distinguish intermittent and persistent
- Formoterol is approved as a rescue inhaler in Europe
  - Is not approved in USA for rescue
- Excellent GINA slide set at: https://ginasthma.org

Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2021. Available from: www.ginasthma.org

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Abbreviations

- “SMART”
- In quality improvement, aim for goals that are:
  - Specific, Measurable, Attainable, Realistic, Timely
- In asthma care:
  - Single Maintenance And Reliever Therapy

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# A 23 yo female has asthma for which she uses her albuterol MDI 3-4x/week. According to GINA 2021, which medication(s) is the best to add to her current regimen?

A. Formoterol bid and for rescue, replacing albuterol
B. Add montelucast 10 mg daily
C. Add ipratropium as a rescue agent alongside albuterol
D. Budesonide/formoterol bid and for rescue, replacing albuterol

# Correct answer is D

- This patient is already on a SABA and not controlled.
- Preferred medication is ICS/formoterol bid and rescue (SMART)
- If continuing SABA, an ICS should be added.
- A LTRA/montelucast is usually added when ICS/LABA is not controlling asthma
- A LABA by itself would never be indicated – poor outcomes with LABA alone or LABA/SABA rescue

# Adults & adolescents 12+ years

**Personalized asthma management**

Assess, Adjust, Review
for individual patient needs




**CONTROLLER** and **PREFERRED RELIEVER**
(Track 1). Using ICS-formoterol as reliever reduces the risk of exacerbations compared with using a SABA reliever

| STEPS 1 – 2 | STEP 3 | STEP 4 | STEP 5 |
|---|---|---|---|
| As-needed low dose ICS-formoterol | Low dose maintenance ICS-formoterol | Medium dose maintenance ICS-formoterol | Add-on LAMA<br>Refer for phenotypic assessment ± anti-IgE, anti-IL5/5R, anti-IL4R<br>Consider high dose ICS-formoterol |
| RELIEVER: As-needed low-dose ICS-formoterol | | | |

**CONTROLLER** and **ALTERNATIVE RELIEVER**
(Track 2). Before considering a regimen with SABA reliever, check if the patient is likely to be adherent with daily controller

| STEP 1 | STEP 2 | STEP 3 | STEP 4 | STEP 5 |
|---|---|---|---|---|
| Take ICS whenever SABA taken | Low dose maintenance ICS | Low dose maintenance ICS-LABA | Medium/high dose maintenance ICS-LABA | Add-on LAMA<br>Refer for phenotypic assessment ± anti-IgE, anti-IL5/5R, anti-IL4R<br>Consider high dose ICS-LABA |
| RELIEVER: As-needed short-acting β2-agonist | | | | |

Other controller options for either track

| | *Low dose ICS whenever SABA taken, or daily LTRA, or add HDM SLIT* | *Medium dose ICS, or add LTRA, or add HDM SLIT* | *Add LAMA or LTRA or HDM SLIT, or switch to high dose ICS* | *Add azithromycin (adults) or LTRA; add low dose OCS but consider side-effects* |
|---|---|---|---|---|

# Low, medium and high ICS doses: adults/adolescents

| Adults and adolescents (12 years and older) | | | |
|---|---|---|---|
| **Inhaled corticosteroid** | **Total daily ICS dose (mcg) – see notes above** | | |
| | **Low** | **Medium** | **High** |
| Beclometasone dipropionate (pMDI, standard particle, HFA) | 200-500 | >500-1000 | >1000 |
| Beclometasone dipropionate (DPI or pMDI, extrafine particle, HFA) | 100–200 | >200–400 | >400 |
| Budesonide (DPI, or pMDI, standard particle, HFA) | 200–400 | >400–800 | >800 |
| Ciclesonide (pMDI, extrafine particle, HFA) | 80–160 | >160–320 | >320 |
| Fluticasone furoate (DPI) | 100 | | 200 |
| Fluticasone propionate (DPI, or pMDI, standard particle, HFA) | 100–250 | >250–500 | >500 |
| Mometasone furoate (DPI) | Depends on DPI device – see product information | | |
| Mometasone furoate (pMDI, standard particle, HFA) | 200-400 | | >400 |

This is NOT a table of equivalence. These are suggested total daily doses for the 'low', 'medium' and 'high' dose treatment options with different ICS.

DPI: dry powder inhaler; HFA: hydrofluoroalkane propellant; ICS: inhaled corticosteroid; pMDI: pressurized metered dose inhaler; * see product information

# Combination ICS/LABA

1. Fluticasone/vilanterol – DPI
    A. 100mcg/25mcg, 200/25
    B. 1 puff qday
2. Fluticasone/salmeterol – DPI and MDI
    A. 100-250-500mcg/50mcg DPI
    B. 45-115-230mcg/21mcg MDI HFA
    C. 2 puffs 2x/day, dose depends on severity
3. Budesonide/**formoterol** – MDI
    A. 80-160mcg/4.5mcg
    B. 2 puffs 2x/day, dose depends on severity
4. Mometasone/**formoterol** – MDI
    A. 50-100-200mcg/5mcg
    B. 2 puffs 2x/day, dose depends on severity

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Other asthma control medications

1. Leukotriene Receptor Antagonists (LTRAs)
    A. Montelukast (Singulair) 10 mg qHS ($10-15 USD/mo)
    B. Zafirlukast (Accolate) 40 mg daily (20mg 2x/day, $30-50 USD/mo)
2. 5-Lipoxygenase Inhibitor
    A. Zileuton 600 mg ER bid (>$1000/mo USD… !!!)

# Other asthma control medications

1. Immunomodulator – Omalizumab (Anti-IgE)
    A. 150-375 mg subcut. INJ q2-4 weeks, $2000 USD/mo
    B. Other biologic therapies
2. Mast cell stabilizer – Cromolyn nebulizer
    A. 1 neb 4x/day, $160-250 USD/mo
3. Methylxanthine – Theophylline
    A. 300-600mg/day, divided daily to bid, $50-60 USD/mo
    B. Multiple toxicities

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Every patient needs an asthma action plan

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Peak flow meters

These two enable setting the three zones



EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Asthma Action Plan

For: _____ Doctor: _____ Date: _____

Doctor's Phone Number _____ Hospital/Emergency Department Phone Number _____

GREEN ZONE

## Doing Well

- No cough, wheeze, chest tightness, or shortness of breath during the day or night
- Can do usual activities

**And, if a peak flow meter is used,**

**Peak flow:** more than _____
(80 percent or more of my best peak flow)

My best peak flow is: _____

**Take these long-term control medicines each day (include an anti-inflammatory).**

| Medicine | How much to take | When to take it |
|---|---|---|
| | | |
| | | |
| | | |
| | | |
| | | |
| Before exercise ❒ _____ | ❒ 2 or ❒ 4 puffs _____ | 5 minutes before exercise |

YELLOW ZONE

## Asthma Is Getting Worse

- Cough, wheeze, chest tightness, or shortness of breath, or
- Waking at night due to asthma, or
- Can do some, but not all, usual activities

**-Or-**

**Peak flow:** _____ to _____
(50 to 79 percent of my best peak flow)

First

**Add: quick-relief medicine—and keep taking your GREEN ZONE medicine.**

_____ (short-acting beta$_2$-agonist)
❒ 2 or ❒ 4 puffs, every 20 minutes for up to 1 hour
❒ Nebulizer, once

Second

**If your symptoms (and peak flow, if used) return to GREEN ZONE after 1 hour of above treatment:**
❒ Continue monitoring to be sure you stay in the green zone.

**-Or-**

**If your symptoms (and peak flow, if used) do not return to GREEN ZONE after 1 hour of above treatment:**
❒ Take: _____ (short-acting beta$_2$-agonist) ❒ 2 or ❒ 4 puffs or ❒ Nebulizer
❒ Add: _____ (oral steroid) mg per day For _____ (3–10) days
❒ Call the doctor ❒ before/ ❒ within _____ hours after taking the oral steroid.

RED ZONE

## Medical Alert!

- Very short of breath, or
- Quick-relief medicines have not helped, or
- Cannot do usual activities, or
- Symptoms are same or get worse after 24 hours in Yellow Zone

**-Or-**

**Peak flow:** less than _____
(50 percent of my best peak flow)

**Take this medicine:**

❒ _____ (short-acting beta$_2$-agonist) ❒ 4 or ❒ 6 puffs or ❒ Nebulizer

❒ _____ (oral steroid) mg

**Then call your doctor NOW.** Go to the hospital or call an ambulance if:
- You are still in the red zone after 15 minutes AND
- You have not reached your doctor.

**DANGER SIGNS**
- **Trouble walking and talking due to shortness of breath**
- **Lips or fingernails are blue**

- **Take ❒ 4 or ❒ 6 puffs of your quick-relief medicine AND**
- **Go to the hospital or call for an ambulance _____ (phone) NOW!**

See the reverse side for things you can do to avoid your asthma triggers.

NHLBI/NIH materials in public domain: http://www.nhlbi.nih.gov/files/docs/public/lung/asthma_actplan.pdf

A 9 yo female presents to the ED with an asthma exacerbation. Her peak flow is only 50% of baseline. She does not improve after two albuterol nebulizers, steroids, supplemental oxygen, or inhaled ipratropium. Which of the following medications may have benefit in this situation?

A. Administration of a mixture of helium and oxygen (Heliox)
B. IV magnesium
C. IV antibiotics
D. Oral montelucast

# Correct answer is B

- IV magnesium has been demonstrated to help recalcitrant asthma cases when other standard therapies have not.
- This has not been shown to be beneficial in adult patients.
- Oral LTRAs have not place in the treatment of acute asthma in the ED
- IV antibiotics can be of benefit for the asthma patient with an underlying infection, but they will take hours to days to improve care
- Heliox may be beneficial in cases of upper airway obstruction (post intubation edema) but has not shown definitive benefit in patients with asthma

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Importance of airway size




Bronchospasm

+

Inflammation

Poiseuille Equation

$$R \sim \frac{1}{r^4}$$

# Asthma diagnosis

- The hallmark is reversible airway obstruction.
- Spirometry shows an increase in the $FEV_1$ of 12% or more after treatment with a beta agonist.
- Usually, the increase is 15-20% - not subtle.
- Additionally, an absolute increase in expired volume of 200 cc or more is required.
- Diagnostic spirometry should be performed when the patient is symptomatic; o/w, the results may be normal.

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Pulmonary function testing

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# How hard is it to do PFT’s?

## Hold out your hand


diagnostic
EasyOne™
ON/OFF
ENTER

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# PFT interpretation in a Family Medicine Clinic

1. **Determine if the $FEV_1$/FVC is low: obstructive pattern**
2. **Determine if the FVC is low: restrictive pattern**
   (If low, consider DLCO – pulmonology office)
3. **Grade the severity**
4. **Determine reversibility for obstructive PFT pattern: asthma vs COPD - Perform post beta agonist PFT**
5. (Consider bronchoprovocation if considering EIB - exercise induced bronchospasm – with methacholine in pulmonology office)

Text in black is probably best done in a pulmonology office

Johnson JD, Theurer WM. A Stepwise Approach to the Interpretation of Pulmonary Function Tests. AFP. 2014 Mar 1; 89(5): 359-366

# Normal Values

- FVC is the total amount of air a person can exhale, usually measured in six seconds.
  - 80 – 120% of predicted is a normal value
  - 70 – 80% demonstrates mild reduction/restriction
  - 50 – 70% demonstrates moderate reduction
  - <50% demonstrates severe reduction
- $FEV_1$ is the amount of air a person can exhale in one second.
  - 80 – 120% of predicted is a normal value

# Normal Values

- $FEV_1$/FVC ratio is the percentage of FVC that can be expired in one second.
  - >80% is normal
  - 50 – 80% demonstrates mild obstruction
  - 30 – 50% demonstrates moderate obstruction
  - <30% demonstrates severe obstruction
- $FEF_{25-75}$ reflects small airway function
  - >80% is normal
  - 60 – 80% reflects mild obstruction in the small airways
  - 40 – 60% reflects moderate obstruction
  - <40% reflects severe obstruction

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Perform test

# PFT Interpretation

- Three steps in interpretation
  - Is the test valid?
  - Interpret the test
  - Classify severity of disease if present

# Validity

- The test is valid is you have good patient effort and the three tests performed are internally consistent.
- You may notice a learning curve in that the latter tests are better performed than the former.
- Make sure that the tests involve maximal effort.  You need to be really aggressive in coaching your patient.

# PFT Interpretation

- Assess FVC, $FEV_1$, and $FEV_1$/FVC ratio.
- FVC and $FEV_1$ normal, with a normal $FEV_1$/FVC ratio:
  - Normal Test …yeah!!!
- FVC normal or low, $FEV_1$ low, and a low $FEV_1$/FVC ratio:
  - Obstructive lung disease
- FVC decreased, $FEV_1$ low or normal, and a normal to high $FEV_1$/FVC ratio:
  - Restrictive lung disease

# PFT Interpretation




| | Actual | Predicted | % Predicted |
|---|---|---|---|
| FVC | 4.0 | 4.5 | 88 |
| FEV1 | 3.4 | 4.2 | 89 |
| $FEV_1/FVC$ | 85 | 82 | 112 |

1. FEV1/FVC?
Normal = 70-80%*
(Go Top→Down)

2. FVC?
Normal > 70%*
Percent predicted
(Go Left→Right)

Normal PFT

# Case #2 - This PFT is best interpreted as:

A. Restrictive pattern
B. Obstructive pattern
C. Small airways disease
D. Normal




| | Actual | Predicted | % Predicted |
|---|---|---|---|
| FVC | 4.0 | 4.5 | 88 |
| FEV1 | 2.4 | 4.2 | 58 |
| FEV1/FVC | 60 | 82 | 76 |
| FEF25-75 | 2.2 | 4.4 | 50 |

# Beta Agonist Challenge

- Perform this when there is a suspicion that the obstructive defect may be reversible –> asthma.
- Give the patient a beta agonist treatment (two puffs of an albuterol MDI or an albuterol nebulizer) and repeat the PFTs several minutes later.  If you notice a 12% or more increase in $FEV_1$, then you have diagnosed reversible airway disease/ asthma.
- In adults > 18 yo, you must additionally have an increase in volume of 200 cc.

# Case #3 - This PFT is best interpreted as:

A. Restrictive pattern
B. Obstructive pattern – reversible
C. Obstructive pattern – not reversible
D. Normal

| | Actual | Predicted | % Predicted |
|---|---|---|---|
| FVC | 4.0 | 4.5 | 88 |
| FEV1 | 2.6 | 4.2 | 57 |
| FEV1/FVC | 65 | 82 | 71 |
| FEF25-75 | 1.7 | 3.6 | 47 |

## Beta agonist treatment

| | Actual | Predicted | % Predicted |
|---|---|---|---|
| FVC | 4.1 | 4.5 | 91 |
| FEV1 | 3.6 | 4.2 | 89 |
| FEV1/FVC | 90 | 82 | 112 |
| FEF25-75 | 3.2 | 3.6 | 91 |

# Case 4

| | Actual | Predicted | % Predicted |
|---|---|---|---|
| FVC | 2.9 | 4.5 | 64 |
| FEV1 | 2.5 | 4.2 | 59 |
| FEV1/FVC | 89 | 82 | 113 |
| FEF25-75 | 3.7 | 3.5 | 102 |


I
aVR
V1
V4
II
aVL
V2
V5
III
aVF
V3
V6
II



EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Case 4

| | Actual | Predicted | % Predicted |
|---|---|---|---|
| FVC | 2.9 | 4.5 | 64 |
| FEV1 | 2.5 | 4.2 | 59 |
| FEV1/FVC | 89 | 82 | 113 |
| FEF25-75 | 3.7 | 3.5 | 102 |



$DL_{CO}$ is decreased when measured

Restrictive lung pattern from Amiodarone

# Case 5

| | Actual | Predicted | % Predicted |
|---|---|---|---|
| FVC | 3.8 | 4.5 | 83 |
| FEV1 | 2.2 | 4.2 | 47 |
| FEV1/FVC | 59 | 82 | 72 |
| FEF25-75 | 1.6 | 3.7 | 43 |



Survey says … COPD

# Case 6

| | Actual | Predicted | % Predicted |
|---|---|---|---|
| FVC | 4.0 | 4.5 | 88 |
| FEV1 | 3.6 | 4.2 | 89 |
| FEV1/FVC | 90 | 82 | 112 |
| FEF25-75 | 3.1 | 3.4 | 95 |

Normal ☺

# Case 7

| | Actual | Predicted | % Predicted |
|---|---|---|---|
| FVC | 4.0 | 4.5 | 88 |
| FEV1 | 3.3 | 4.2 | 81 |
| FEV1/FVC | 83 | 82 | 101 |
| FEF25-75 | 1.7 | 3.5 | 48 |

Small Airways Defect

# Case 8

| | Actual | Predicted | % Predicted |
|---|---|---|---|
| FVC | 3.5 | 5.3 | 68 |
| FEV1 | 3.1 | 4.6 | 68 |
| FEV1/FVC | 93 | 82 | 117 |
| FEF25-75 | 3.7 | 3.3 | 120 |

The patient's BMI = 47

…

Restrictive pattern in obese patient

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Pulmonary Miscellaneous

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Pulmonary Hypertension

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Pulmonary **arterial** hypertension is most likely in which disease state?

A. Heart Failure
B. Sickle Cell Disease
C. COPD/Interstitial lung disease
D. Scleroderma
E. Chronic veno-occlusive disease (recurrent PE)

# Correct answer is D
# Pulmonary Hypertension

- Group 1 — Pulmonary **arterial** HTN
- Group 2 — Left heart disease (HF and valve)
- Group 3 — Lung disease/hypoxia
- Group 4 — Chronic thromboembolic disease
- Group 5 — Multifactorial

Dunlap B, Weyer G. Pulmonary Hypertension: Diagnosis and Treatment. Am Fam Phys. 2016 Sep 15:94 (6):463-469

# Pulmonary HTN

- Pulmonary *arterial* hypertension is a primary disease of the pulmonary arteries.
- The term “Pulmonary hypertension” comprises 5 clinical categories.

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# CXR findings in Pulmonary Hypertension



# Normal arterial tree on Left





# Diagnostic tests

- PFTs to confirm COPD or ILD/restrictive lung disease
- V/Q scan to detect mismatching of perfusion: normal V/Q excludes PH with sensitivity 96% and specificity 90%
  - Follow up with CT-angiogram or PA angiogram

[redacted]

| | |
|---|---|
| | 9 in |
| | lbs, BMI 40.1 |
| Gender | FEMALE |
| Ethnic | CAUCASIAN |
| Smoker | NO |
| Asthma | YES |

**Test Information** * 8634634v13122 Single Page ClinDoc

| | |
|---|---|
| Test Date/Time | 03/20/2018 09:07pm |
| Post Time | 09:34pm |
| Test Mode | DIAGNOSTIC |
| Interpretation | GOLD/Hardie |
| Predicted Ref | NHANES III |
| Value Select | BEST VALUE |
| Tech ID | |
| Automated QC | ON |
| BTPS (IN/EX) | -.--/ 1.02 |

**Test Results** Your FEV1 is 58% Predicted

| | Pre-Test | | | | | | Post-Test | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Parameter | Best | Trial3 | Trial4 | Trial2 | Pred | %Pred | Best | Trial4 | Trial2 | Trial5 | Chg |
| FVC[L] | 2.48* | 2.48* | 2.38* | 2.27* | 4.05 | 61 | 3.19* | 3.19* | 2.94* | 2.57* | 29%* |
| FEV1[L] | 1.84* | 1.84* | 1.79* | 1.71* | 3.17 | 58 | 2.23* | 2.23* | 2.07* | 1.81* | 21%* |
| FEV1/FVC | 0.74 | 0.74 | 0.75 | 0.75 | 0.79 | 94 | 0.70 | 0.70 | 0.71 | 0.68* | |
| PEF[L/min] | 345 | 345 | 334 | 265* | 439 | 79 | 333 | 333 | 320* | 278* | -3% |
| FEF25-75[L/s] | 1.33* | 1.33* | 1.37* | 1.34* | 2.85 | 47 | 1.25* | 1.25* | 1.25* | 0.89* | -7% |
| FET[s] | 5.29 | 5.29 | 4.52 | 5.59 | -.-- | -- | 9.74 | 9.74 | 7.07 | 9.39 | |

* Indicates Below LLN or Significant Post Change

| | | |
|---|---|---|
| Pre-Test | FEV1 Var=0.04L 2.4%; | FVC Var=0.10L 3.9%; Session Quality A |
| Post-Test | FEV1 Var=0.15L 6.9%; | FVC Var=0.25L 7.9%; Session Quality B |
| Interpretation | Restriction probable: further examinations recommended | |
| Caution: Maneuvers Not Reproducible - Interpret With Care. | | |




EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# PFT showing restrictive pattern

Pre-Test

| Parameter | Best | Trial3 | Trial4 | Trial2 | Pred | %Pred | Po |
|---|---|---|---|---|---|---|---|
| FVC[L] | 2.48* | 2.48* | 2.39* | 2.27* | 4.05 | 61 | |
| FEV1[L] | 1.84* | 1.84* | 1.79* | 1.71* | 3.17 | 58 | |
| FEV1/FVC | 0.74 | 0.74 | 0.75 | 0.75 | 0.79 | 94 | |
| PEF[L/min] | 345 | 345 | 334 | 265* | 439 | 79 | |
| FEF25-75[L/s] | 1.33* | 1.33* | 1.37* | 1.34* | 2.85 | 47 | |

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# What Pulmonary Artery pressure on echocardiography is suggestive of pulmonary hypertension?

A. > 20 mm Hg
B. > 35 mm Hg
C. > 45 mm Hg
D. > 60 mm Hg

# Echocardiography

- Pulmonary artery pressure > 35 mm Hg
- Frequently an incidental finding in a patient with chronic HF, or mitral/aortic valve pathology

Dunlap B, Weyer G. Pulmonary Hypertension: Diagnosis and Treatment. Am Fam Phys 2016 Sep 15;94(6):463-469

# Echo vs Right Heart Cath

- Meta-analysis conducted for diagnosis of pulm HTN
- Sensitivity of 83%
- Specificity of 72%
- (+) likelihood ratio = 3.0
- (-) likelihood ratio = 0.24

Janda S, Shahidi N, Gin K*, et al.* Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis *Heart* 2011;**97:**612-622.

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

A 27 yo female presents with a painful lesion on her anterior shins for 2 weeks. Her chest xray shows mediastinal lymphadenopathy.
What is the most likely diagnosis?


Top drawer of exam table:
KOH /Wet Mounts
GC/Chlamydia Probes
Pap Kits
OB/GYN Swabs
HPV Swabs
Culturettes
Hemocult Cards and Developer
K-Y Jelly
Fixative
Lab Bags
Bottom drawer of exam table:
4 small and 8 medium Welch Allen Disposable Speculums
3 Metal Speculums




EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# A 27 yo female presents with a painful lesion on her anterior shins for 2 weeks. Her chest xray shows mediastinal lymphadenopathy. What is the most likely diagnosis?

A. Pulmonary TB
B. Lymphoma
C. Erythema multiforme
D. Sarcoidosis






EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Correct answer is D

- Sarcoidosis has multiple presentations
- In Ddx of erythema nodosum –
  a painful panniculitis
  commonly on the anterior shins.
- In the lungs, staging is 0-4:
- Noncaseating granulomas

**Staging of Sarcoidosis on the Basis of Chest Radiographs**

| | | |
|---|---|---|
| STAGE 0 | No abnormalities | 5%–10% |
| STAGE 1 | Lymphadenopathy (fig. A) | 50% |
| STAGE 2 | Lymphadenopathy + pulmonary infiltration (fig. B) | 25%–30% |
| STAGE 3 | Pulmonary infiltration (fig. C) | 10%–12% |
| STAGE 4 | Fibrosis | 5% (up to 25% during the course of the disease) |



EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# In a 35 yo male patient who smokes regularly, 2 ppd for the past 10 years, which routine immunization is recommended by the CDC to prevent disease?

A. Pneumococcal PPSV23
B. Shingrix (Zoster)
C. Meningococcal vaccine
D. Hepatitis C vaccine

# Correct answer is A

- The CDC recommends the PPSV23 vaccine for all patients who smoke.
- Shingrix to prevent zoster reactivation and post herpetic neuralgia in recommended at age 50
- Meningococcal vaccination is recommended for immunocompromised patients and those with functional asplenia, in general.
- There is not yet a vaccine for hepatitis C.

# Of note, a new pneumococcal vaccine has been released – PCV15 and PCV 20.

Should not be on a board exam for at least 1-2 years

# TB screening interpretation - CDC

- For low risk patients, the PPD must be > 15 mm in diameter of induration for a (+) test.
- > 10 mm is (+) for patients with high endemic states, IV drug users, high congregant settings (nursing homes), diabetes, severe CKD, children < 5 yo or children exposed to high risk adults
- > 5 mm is (+) for patients living with HIV, close contact of patient with TB, organ transplant recipients, and immunocompromised patients or patients prednisone 15 mg/day or more

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

A healthy 28 yo patient is screened for TB with the PPD test and it is (+). The CXR is normal and the patient is asymptomatic. What is the best therapy to decrease the reactivation of tuberculosis in this patient?

A. Rifampin 300 mg daily for 2 months
B. Isoniazid 300 mg daily for 9 months
C. Streptomycin + pyrazinamide x 12 weeks
D. INH, pyrazinamide, rifampin, and ethambutol x 12 weeks

# Correct answer is B

- In a healthy patient, INH is sufficient to prevent TB reactivation.
- Duration of INH therapy is 6-9 months.
- May consider using vitamin B6 to minimize risk of neuropathy from INH – 50 mg po daily
- If using rifampin alone, the dose is 600 mg and the duration is at least 4 months – double the dose and duration of that in the given answer
- Four drug therapy is used to initially treat active TB until the resistance pattern is known.

A 46 yo female is in a car accident and sustains a mid femur fracture. She is stabilized, but on hospital day #2 develops progressive shortness of breath. A chest xray demonstrates diffuse fluffy infiltrates bilaterally. What is the most likely diagnosis?

A. Pneumococcal Pneumonia
B. Fat Embolism
C. Acute heart failure
D. Pulmonary embolism



# Correct answer is B

- This is a classic case presentation of fat embolism syndrome.
- Fat embolism usually occurs after a long bone fracture with a significant amount of bone marrow fat entering the blood stream and embolizing to the lungs.
- This must be recognized quickly and treated with active supportive care, to include mechanical ventilation.
- The other choices are all possible but do not fit the history as well.

A 27 yo female presents with persistent clear rhinorrhea, nasal itching, and sneezing. She does not have any pets. She had asthma as a child but has not used an inhaler in a decade. She has no dyspnea. The exam demonstrates boggy nasal turbinates but is o/w nl. The lungs are clear. What medication is best for treating this condition?

A. Nasal fluticasone 1 puff each nostril daily to bid
B. Oral loratadine 10 mg daily
C. Oral pseudoephedrine 40 mg up to tid prn
D. Oral montelucast 10 mg daily

# Correct answer is A

- This patient has allergic rhinitis AR
- All the options presented are potential treatments for AR
- Nasal steroids have the best outcomes for initial treatment
- No one nasal steroid is superior to others
  - Fluticasone, mometasone, triamcinolone
- Often, patients will benefit from a combination of therapies
- Antibiotics have no place in treating AR, in general

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Venous thromboembolism

## DVT and PE

A 57 yo male underwent right inguinal herniorrhaphy 2 weeks ago. He presents with acute dyspnea, RR 32, pulse ox = 86% on room air, pulse 124, and BP 88/54. You suspect PE and this is confirmed with CT. What is the best treatment in this case?

A. IV heparin to achieve a PTT of 60-100 (therapeutic)
B. Low molecular weight heparin 1 mg/kg bid
C. Apixaban 5 mg po bid
D. Emergent thrombolysis

# Correct answer is D

- The first three choices are all acceptable for a patient with a stable pulmonary embolus.
- However, this patient has hypotension.  The echocardiogram may show elevation in the pulmonary artery/right heart pressures.
- The EKG may show signs of acute right heart strain – S1Q3T3
- These patients should be considered for emergent catheter-based thrombolysis.
- (Picture saddle embolus)



EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Pulmonary Embolus
# Hampton's Hump





# DVT

- Use the Well's DVT criteria to assess patient risk
- ≤ 0, low risk, 5% prevalence of DVT
- 1-2, moderate risk, 17% prevalence
- ≥ 3, high risk, 17-53% prevalence of DVT
- If pt is low-moderate risk, check d-dimer → negative, d/c
  - Positive d-dimer → U/S
- If pt is high risk, check U/S as first step.

# VTE treatment

- Stable patients can be assessed and discharged in the outpatient realm/ED
- Start Factor X inhibitor or thrombin inhibitor
  - Rivaroxaban, apixaban, edoxaban, and others
  - Dabigatran
- Can be considered in stable PE patients as well, although many are still admitted
- Warfarin still an option
  - Requires initiation and transient hypercoagulable state
  - LMWH until INR therapeutic at 2.0 – 3.0

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Pulmonary infections

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

A 67 yo female with steroid dependent COPD on prednisone 20 mg daily for the past two months develops pneumonia. Which pathogen below should be especially targeted in the choice of initial antibiotics?

A. Mycoplasma pneumonia
B. Pseudomonas aeruginosa
C. Staphylococcoccus aureas
D. Streptococcus pneumonia

# Correct answer is B

- This patient is high risk and should be treated beyond the usual standards for CAP – community acquired pneumonia.
- The selection of initial antibiotics should resemble that for health-care associated pneumonia.
- The most significant/pathologic organism to target is pseudomonas.
- Mycoplasma is commonly associated with “walking pneumonia” – CAP
- Streptococcus may have acute onset of rigors/chills and have a lobar pattern.
- Staph aureus may be associated with IV drug use and be associated with lung abscess.

A 39 yo female has had a cough for 2 weeks – o/w feels well. She has no other PMHx. Works in banking. No COVID exposures and is Trivaxxed. She has a temp of 37.7 and has bilateral inspiratory rales in the mid lung fields. CXR as seen. Which of the following bacteria is least likely to cause this pneumonia?

A. Mycoplasma pneumonia
B. Legionella pneumonia
C. Chlamydia pneumonia
D. Streptococcus pneumonia



# Correct answer is D

- This patient has mild pneumonia, or “walking pneumonia.”
- Her CURB-65 score is 0, meaning low risk → outpatient treatment
- Her PORT/PSI score is 29 (age – 10) → risk class I, 0.1% mortality
- The first three bacteria may have an insidious onset and can potentially resolve on their own.
- Treatments for CAP specifically target these bacteria and include macrolides (azithromycin, clarithromycin) and tetracycline class meds (doxycycline).

# Community-acquired pneumonia Treatment

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

- Oral penicillins are still excellent first line therapies
  - High dose amoxicillin (amox+clavulanate)
  - Some authorities add a macrolide to this (preferred over doxycycline)
- If suspicion for non-pneumococcal infection, consider macrolide/ doxycycline first
- If allergic to PCN and can tolerate cephalosporin:
  - Cefpodoxime preferred (oral third generation)
- If above agents cannot be used, consider respiratory quinolone:
  - Levofloxacin, moxifloxacin, gemifloxacin

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Chest radiography

# Acute shortness of breath and chest pain



A. Tension pneumothorax

B. Pulmonary embolus

C. Emphysema

D. Mass c/w cancer

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

With no layering of the fluid, the most likely diagnosis is:



A. Pleural effusion

B. Tumor

C. Empyema

D. Cardiomegaly

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Pulmonary edema



- Enlarged cardiac silhouette
- Cephalization
- No effusion
- Sharp heart borders

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Acute pulmonary edema



EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Cephalization



EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Vascular/hilar fullness





EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Kerley B lines Interstitial Fluid




>90°
Left
Atrium
*

# Elderly man with hypotension



# Free air under the diaphragm




EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Pleural Effusion








EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة


A
B

# Technique for percussion

- Standard is to percuss with stethoscope or reflex hammer
  - Difficult in patients with increased BMI
- Percuss the ipsilateral clavicle
  - The tap transmits quite well

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Clavicular Percussion



EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Pulmonary Abscess



# Interstitial Lung Disease

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة



# Honeycomb lung




DFOV 27.0cm
BONE
R
WW 1400
WL 170

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# COPD

The gold standard for diagnosing COPD is:

A. History and physical exam
B. Chest x-ray
C. Spirometry
D. Assay for alpha-1-antitrypsin levels
E. CT scan of the chest

# Steps in evaluation of COPD

1. Spirometry to diagnosis/confirm
2. Grade airflow limitation
3. Assess disease severity
4. Assess exacerbation risk

# Step 1 - Spirometry

- In patients with dyspnea, chronic cough, or sputum production and a hx of exposure to risk factors, **spirometry is a must to make the diagnosis.**
- Spirometry provides vital information in assessing the severity of disease and to assist with disease management and should be **repeated annually**.
- Spirometry is positive if the post-bronchodilator **FEV1/FVC ratio is < 0.70** indicating persistent airflow limitation.
- Spirometry is underutilized potentially leading to misdiagnosis

## Leading Causes of Death*
## United States, 2000




## Actual Causes of Death†
## United States, 2000




*Source: Minino AM, Arias E, Kochanek KD, Murphy SL, Smith BL. Deaths: final data for 2000. National Vital Statistics Reports 2002; 50(15):1-20.

†Source: Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291 (10): 1238-1246.

# DDx of a fixed obstructive pattern

- COPD – chronic obstructive pulmonary disease
- Asthma (Can become fixed with a reversible component)
- Alpha-1 antitrypsin deficiency
- Bronchiectasis
- Bronchiolitis obliterans
- Cystic fibrosis

Johnson JD, Theurer WM. A Stepwise Approach to the Interpretation of Pulmonary Function Tests. *Am Fam Physician*. 2014 Mar 1;89(5):359-366

# Step 2 – Grade Airflow Limitation

- COPD severity determined by degree of airflow limitation on spirometry:
  - GOLD 1: mild — FEV1 > 80% predicted
  - GOLD 2: moderate — FEV1 51-80% predicted
  - GOLD 3: severe — FEV1 31-50% predicted
  - GOLD 4: very severe — FEV1 < 30% predicted

Executive Summary: Global Initiative for Chronic Obstructive Lung Disease, Updated 2021

# COPD Assessment Test*
# (or similar assessment)

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

- 8 statements re symptoms or possible limitations
- Each statement is rated from 0 to 5 - max of 40 points; ≥ 10 is high risk
  - I never cough
  - I have no phlegm in my chest at all
  - My chest does not feel tight at all
  - When I walk up a hill or flight of stairs I am not breathless
  - I am not limited doing any activities at home
  - I am confident leaving my home despite my lung condition
  - I sleep soundly
  - I have lots of energy

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Modified Medical Research Council Dyspnea Scale (mMRC)

- **0 points -** dyspnea only with strenuous exercise
- **1 point -** dyspnea when hurrying or walking up a slight hill
- **2 points -** walks slower than people of same age because of dyspnea or has to stop for breath when walking at own pace
- **3 points -** stops for breath after walking 100 yards or after a few minutes
- **4 points -** too dyspneic to leave house or dyspneic when dressing

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# COPD GOLD Criteria and GOLD combined assessment (MDCalc is $Free.99)









EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة


6:50
GOLD COPD Criteria
CALCULATOR
NEXT STEPS
EVIDENCE
CREATOR
of dyspnea or has to stop for breath when walking at own pace; CAT 10 = COPD symptoms have low-medium impact on patient's life
Higher (mMRC ≥2 or CAT Score ≥10)
Exacerbation history
0 exacerbations
1 exacerbation without hospital admission
≥1 exacerbation with hospital admission
≥2 exacerbations
RESULT
GOLD D
Grade 3 airflow obstruction
20.1 %
3-year mortality
LAMA + LABA recommended, plus ICS if frequent exacerbations


RESULT
GOLD D
Grade 3 airflow obstruction
20.1 %
3-year mortality
LAMA + LABA recommended, plus ICS if frequent exacerbations

# Helpful apps
# Peak Flow estimates




EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# GOLD Groups

A. Low risk/less symptoms GOLD 1-2

FEV1 > 50%, ≤ 1 exacerbation/yr, CAT < 10 or mMRC 0-1

B. Low risk/more symptoms GOLD 1-2

FEV1 > 50%, ≤ 1 exacerbation/yr, CAT ≥ 10 or mMRC ≥ 2

C. High risk/less symptoms GOLD 3-4

FEV1 < 50%, ≥ 2 exacerbations/yr, CAT < 10 or mMRC 0-1

D. High risk/more symptoms GOLD 3-4

FEV1 < 50%, ≥ 2 exacerbations/yr, CAT ≥ 10 or mMRC ≥ 2

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

A 57 yo male with COPD currently uses his rescue albuterol/ipratropium inhalers 3-4x/day most days. No recent exacerbations. The addition of which medication would be the next best step?

A. Prednisone 20 mg po daily
B. Fluticasone inhaled 220 mcg 2 puffs bid
C. Tiotropium 2 puffs daily
D. Montelukast 10 mg daily

# Correct answer is C

- This patient is currently on SABA/SAMA
- Adding either a LABA or a LAMA to this patient's care would be the next best step.
- He has not had any recent exacerbations.  Thus, no indication for ICS
- Montelucast/LTRA can be used in asthma but are not routinely used in COPD w/o other medical conditions (SAR)

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Initial Pharmacologic Management of COPD

- Group A
  - FEV1 > 50%, ≤1 exacerbation/yr, CAT <10 or mMRC 0-1
  - First choice: SABA or SAMA as needed
  - Alternatives:
    - LAMA
    - LABA
    - SABA/SAMA combination
  - Other possibility: theophylline

# Management (continued)

- Group B
  - FEV1 > 50%, ≤ 1 exacerbation/yr, CAT ≥ 10 or mMRC ≥ 2
  - First choice: LABA or LAMA
  - Alternative: LABA and LAMA
  - Other possibilities: SABA and/or SAMA, theophylline

# Management (continued)

- Group C
  - FEV1 < 50%, ≥ 2 exacerbations/yr, CAT < 10 or mMRC 0-1
  - First choice: LAMA, or LABA/ICS
  - Alternatives:
    - LAMA and LABA
    - LAMA and PDE-4 I
    - LABA and PDE-4 I
  - Other possibilities: SABA and/or SAMA, theophylline

# Management (continued)

- Group D
  - FEV1 < 50%, ≥ 2 exacerbations/yr, CAT ≥ 10 or mMRC ≥ 2
  - First choice: LABA/ICS and/or LAMA
  - Alternatives:
    - LABA/ICS and LAMA
    - LABA/ICS and PDE-4 I
    - LAMA/LABA
    - LAMA and PDE-4 I
  - Other possibilities: SABA and/or SAMA, theophylline


No curative power is claimed for PHILIP MORRIS . . . but
AN OUNCE OF PREVENTION
is Worth a Pound of Cure!
PHILIP MORRIS
are scientifically proved far less irritating to the smoker's nose and throat.
CALL FOR PHILIP MORRIS

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

A 73 yo female has  a 60 pk yr history of tobacco abuse.  According to the USPSTF (United States Preventive Services Task Force), this patient should be screened with PFTs to assess for COPD.

A. True
B. False

# Correct answer is B

- Even with a high pk yr history, there is no patient benefit to screen for COPD in an asymptomatic patient.
- Conversely, this patient should be offered lung cancer screening with low dose chest CT.
- USPSTF Recommendations for screening
- http://epss.ahrq.gov/ePSS/GetResults.do?new=true
- **Screening for COPD in asymptomatic patients is a Grade D recommendation**
  - **Not recommended**
  - Last updated 2016
- ACP and GOLD do not recommend screening in asymptomatic patients → lack of clinical benefit

# Short-Acting Beta Agonists

- **Albuterol**, metaproterenol, levalbuterol
  - **Albuterol/ipratropium combination**
- **Mechanism of action: relax smooth muscles**
- **Duration of action: approx. 4-6 hours**
- Benefits: decrease dyspnea, improve ability to function
- Side effects: tachycardia, jitteriness, cardiac dysrhythmias in some, increase in tremor, hypokalemia in patient's on kaliuretic drugs
- Misc: Teach proper technique; recommend use with **spacer**
- MDI preferred: avoid oral SABAs if possible
- **No decrease in mortality**

# Long-Acting Beta Agonists

- Salmeterol, formoterol – inhalers used **twice daily**
- Indacaterol, olodaterol – inhalers used **once daily**
- Arformoterol – nebulizer solution used twice daily
- Mechanism of action: relax smooth muscles
- Duration of action: approx. 12-24 hours
- Benefits: decrease dyspnea, improve ability to function, decrease hospitalization rates (salmeterol, formoterol), decrease exacerbation rates (salmeterol, formoterol, indacaterol)
- Side effects: similar to SABAs
- **No decrease in mortality; increase in mortality in COPD/asthma overlap and in asthma**

# Short-Acting Muscarinic Antagonists

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

- **Ipratropium**
- Mechanism of action: bronchodilation by blocking M2 and M3 receptors
- Duration of action: approx. 6-8 hours
- Benefits: decrease dyspnea, improve ability to function
- Side effects: dry mouth, bitter taste
- Misc: teach proper technique; recommend use with spacer
- **No decrease in mortality**

# Long-Acting Muscarinic Antagonists

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

- **Tiotropium, umeclidinium, glycopyrronium bromide – inhalers used once daily**
- **Aclidinium – inhaler used twice daily**
- Mechanism of action: bronchodilation by blocking M2 and M3 receptors
- Duration of action: approx. 12-24 hours
- Benefits: decrease dyspnea, improve ability to function, decrease in exacerbations and hospitalizations
- Side effects: dry mouth, bitter taste
- **No decrease in mortality**

# Inhaled Corticosteroids

- Beclomethasone, fluticasone proprionate, budesonide
  - Fluticasone furoate duration of action is 24 hours
- Mechanism of action: uncertain
- Duration of action: 12 hours
- Benefits: improves symptoms and quality of life, **reduces exacerbations in patients with an FEV1 < 60% predicted**
- **Does not modify long-term decline of FEV1 or decrease mortality**

# Other Agents

- Antibiotics – Use for acute exacerbations. Avoid chronic use
- Mucolytics – may reduce exacerbations per Cochrane review. No improvement in QOL
- Antitussives – avoid use in stable COPD as cough has a protective role
- Opioids – effective for dyspnea in patients with severe disease

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# A 63 yo male has COPD and currently uses tiotropium bid, and albuterol/ipratropium combination for dyspnea. Which blood test would suggest benefit from the addition of an ICS?

A. Blood eosinophilia > 300
B. WBC > 15,000 cells
C. Platelet count > 450K
D. Creatinine > 1.5 mg/dL

# Correct answer is A

- Recent evidence suggests potential benefit from starting ICS when blood eosinophil count is > 300.
- Additionally, for patients having ≥ 1 exacerbations in a year, ICS has benefit
- The other lab values, while abnormal, are not indications to add ICS

# COPD Care in 2020 recommendations

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

- Blood eosinophil count: if > 300, consider ICS for therapy
- For escalating therapy beyond SABA/SAMA:
  - Start with LAMA
    - Then add LABA
  - Add ICS if > 1 exacerbation/year or > 300 Eosinophil count
- For recalcitrant cases (consult pulmonology) :
  - Consider adding roflumilast/ Daliresp, a PDE4I
  - Consider lung reduction surgeries or lung transplant

Labaki WW and Rosenberg SR. Chronic obstructive pulmonary disease. *Ann Intern Med* 2020 Aug 4; 173:ITC17. (https://doi.org/10.7326/AITC202008040)

# American Thoracic Society Guidelines April 2020

- For COPD patients with dyspnea or exercise intolerance, use LABA/LAMA rather than monotherapy with either medication.
- For patients on LABA/LAMA with persistent sx and 1 or more COPD exacerbations in the prior year, add ICS.
- For stable patients on triple therapy with LABA/LAMA/ICS who have not had an exacerbation in the prior year, consider deprescribing ICS.
- For patients on optimal therapy with frequent exacerbations, the group advises against maintenance oral steroid therapy

Am J Respir Crit Care Med Vol 201, Iss 9, pp e56–e69, May 1, 2020

# COPD Triple therapy vs Dual therapy

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

- 8500 patients with at least 1 COPD exacerbation in prior year.
- Four groups
  - Budesonide 160 ug + formoterol + glycopyrrolate (low dose triple therapy)
  - Budesonide 320 ug + formoterol + glycopyrrolate (high dose triple therapy)
  - Budesonide 320 ug + formoterol (ICS/LABA)
  - Formoterol + glycopyrrolate (LABA/LAMA)
- At one year follow, the **triple therapy groups had less exacerbations**:
  - 1.08 and 1.07 versus 1.42 and 1.24
- **All cause mortality was lower with the high dose triple therapy** vs LABA/LAMA at 1.3% vs 2.3% (NNT = 100)
- Incidence of PNA higher in triple therapy groups at 3.5 and 4.5% vs 2.3% in the LABA/LAMA group (NNH = 83 and 45 respectively)

Rabe KF et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. *N Engl J Med* 2020 Jul 2; 383:35.

# ICS and fracture risk

- Meta-analysis of 16 trials with 9143 ICS users and 8370 controls
- Most patients had severe COPD and were men
- Mean duration of studies = 90 weeks (~ 2 years)
- **Fracture risk rose significantly with ICS use**
  - **180 fractures in ICS users; 141 in controls (OR 1.27, p = 0.04)**
- Authors also reviewed 7 controlled observational studies with 69,000 patients – similar fx risk (OR 1.21, p<0.0001)
- **Use ICS as appropriate – be aware of risk of fracture**

Loke YK et al. Risk of fractures with inhaled corticosteroids in COPD: Systematic review and meta-analysis of randomised controlled trials and observational studies. *Thorax* 2011 Aug; 66:699

Recent evidence suggests that the use of beta blockers in patients with COPD is not harmful, and perhaps protective.

A. True
B. False

# Correct answer is A

- BB use in patients with COPD is neutral to positive on outcomes.
- BB use in asthma can still be harmful in a minority of patients and should only be prescribed when the perceived benefits outweigh harms.

# β-blockers in COPD patients #1

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

- Traditional concern is worsening of COPD control in patients placed on β-blocker.
- Retrospective cohort study with 6000 Scottish patients with COPD.
- 819 patients used β-blockers over a 4.4 year period.
  - 88% of β-blockers were cardioselective
- 1/3 of patients died
- **β-blocker use was associated with a 22% lower all cause mortality.**
- **β-blockers had no adverse effect on lung function**

Short PM et al. Effect of β blockers in treatment of chronic obstructive pulmonary disease: A retrospective cohort study. *BMJ* 2011 May 10; 342:d2549

# β-blockers in COPD patients #2

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

- **2230 COPD patients** in the Netherlands on β-blockers followed for **7 years**.
- The mean (SD) age of the patients with COPD was 64.8 (11.2) years at the start of the study, and 53% of the patients were male
- **The adjusted hazard ratios of β-blocker use for mortality was 0.68 (95% CI, 0.56-0.83).**
- **The adjusted hazard ratios for exacerbation of COPD was 0.71 (95% CI, 0.60-0.83).**
- **Patients on β-blockers were 30% less likely to die from any cause or experience a COPD exacerbation**

Rutten FH et al. β-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. *Arch Intern Med* 2010 May 24; 170:880.

# COPD highlights

- No USPSTF indication to screen asymptomatic patients.
- May start with either LABA or LAMA when patients have moderate-to-severe COPD
- Use ICS to reduce frequency of exacerbations
- Consider pulmonary rehab in any patient with mild COPD or worse
- B-blockers not harmful in COPD patients.

EMIRATES FAMILY MEDICINE SOCIETY
شعبة الإمارات لطب الأسرة

# Thanks for your attention

## Contact:

Eddie.Needham.MD@AdventHealth.com


# Finding the color in a gray world

Eddie.Needham.MD@AdventHealth.com